Physician profile
Robert David Brown
NPI 1548689037
$608.35
in general payments reported to CMS, 2019-2025
15 companies · $400 in 2025
The $400 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2023: $18.44 · 2024: $80.66 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $498.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $96.84 | 2019-2025 | Xtandi, Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $94.73 | 2025 | |
| Neotract INC. | $58.54 | 2019 | |
| Novartis Pharmaceuticals Corporation | $50.24 | 2025 | |
| Boston Scientific Corporation | $42.91 | 2024-2025 | Ams 700, Axonics |
| Coloplast Corp | $41.57 | 2024 | |
| Urogen Pharma, INC. | $34.23 | 2025 | |
| Accord Healthcare, INC. | $32.59 | 2025 | |
| Sumitomo Pharma America, INC. | $27.70 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $25.35 | 2025 | Keytruda |
| Progenics Pharmaceuticals, INC. | $24.38 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $22.63 | 2025 | Lynparza |
| Pfizer INC. | $20.70 | 2025 | |
| Abbvie INC. | $19.40 | 2025 | |
| Ferring Pharmaceuticals INC. | $16.54 | 2024 | Adstiladrin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.